CNS Pharmaceuticals (CNSP) Competitors $6.48 +0.41 (+6.75%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$6.05 -0.43 (-6.64%) As of 08/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNSP vs. BFRG, CSCI, CARM, IMCC, FLGC, GOVX, PHIO, PHXM, LGVN, and SONNShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Bullfrog AI (BFRG), COSCIENS Biopharma (CSCI), Carisma Therapeutics (CARM), IM Cannabis (IMCC), Flora Growth (FLGC), GeoVax Labs (GOVX), Phio Pharmaceuticals (PHIO), PHAXIAM Therapeutics (PHXM), Longeveron (LGVN), and Sonnet BioTherapeutics (SONN). These companies are all part of the "pharmaceutical products" industry. CNS Pharmaceuticals vs. Its Competitors Bullfrog AI COSCIENS Biopharma Carisma Therapeutics IM Cannabis Flora Growth GeoVax Labs Phio Pharmaceuticals PHAXIAM Therapeutics Longeveron Sonnet BioTherapeutics Bullfrog AI (NASDAQ:BFRG) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Do analysts prefer BFRG or CNSP? CNS Pharmaceuticals has a consensus price target of $300.00, suggesting a potential upside of 4,529.63%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Bullfrog AI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CNS Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, BFRG or CNSP? Bullfrog AI has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500. Which has better earnings & valuation, BFRG or CNSP? Bullfrog AI has higher revenue and earnings than CNS Pharmaceuticals. Bullfrog AI is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBullfrog AI$60K213.36-$6.99M-$0.76-1.67CNS PharmaceuticalsN/AN/A-$14.86M-$3.75 thousand0.00 Is BFRG or CNSP more profitable? CNS Pharmaceuticals' return on equity of -183.89% beat Bullfrog AI's return on equity.Company Net Margins Return on Equity Return on Assets Bullfrog AIN/A -195.35% -162.37% CNS Pharmaceuticals N/A -183.89%-139.37% Does the media favor BFRG or CNSP? In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 1 mentions for CNS Pharmaceuticals and 0 mentions for Bullfrog AI. CNS Pharmaceuticals' average media sentiment score of 0.34 beat Bullfrog AI's score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Bullfrog AI Neutral CNS Pharmaceuticals Neutral Do insiders & institutionals have more ownership in BFRG or CNSP? 1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 24.7% of Bullfrog AI shares are held by company insiders. Comparatively, 0.1% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryCNS Pharmaceuticals beats Bullfrog AI on 9 of the 13 factors compared between the two stocks. Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.72M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E RatioN/A21.2831.3626.05Price / SalesN/A347.16434.71196.83Price / CashN/A43.1937.7358.48Price / Book0.288.129.536.61Net Income-$14.86M-$54.72M$3.26B$265.65M7 Day Performance27.31%2.62%2.12%2.02%1 Month Performance-21.07%2.68%2.80%-0.32%1 Year Performance-94.46%10.93%30.68%19.06% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals1.1871 of 5 stars$6.48+6.8%$300.00+4,529.6%-93.8%$3.72MN/A0.005News CoverageAnalyst UpgradeShort Interest ↑Gap UpBFRGBullfrog AI0.407 of 5 stars$1.27flatN/A-53.0%$11.96M$60K-1.574CSCICOSCIENS BiopharmaN/A$3.59-0.4%N/AN/A$11.31M$9.59M-0.6220CARMCarisma Therapeutics2.9892 of 5 stars$0.28+2.0%$1.93+598.7%-80.2%$11.28M$19.63M-0.1820News CoverageShort Interest ↓IMCCIM Cannabis0.4914 of 5 stars$2.93+6.9%N/A-20.7%$11.08M$39.44M-4.58340FLGCFlora Growth3.3035 of 5 stars$20.60+9.7%$93.00+351.5%-44.7%$10.84M$59.51M-0.60280High Trading VolumeGOVXGeoVax Labs1.849 of 5 stars$0.68+0.1%$8.88+1,205.5%-89.5%$10.81M$3.95M-0.3410Short Interest ↑Gap UpPHIOPhio Pharmaceuticals2.888 of 5 stars$2.13-5.3%$14.00+557.3%-31.7%$10.80MN/A-0.3310Analyst DowngradeGap UpPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049LGVNLongeveron3.5406 of 5 stars$0.70+2.6%$8.67+1,146.5%-69.6%$10.29M$2.39M-0.1120High Trading VolumeSONNSonnet BioTherapeutics3.0118 of 5 stars$3.07-4.7%$20.00+551.5%-38.1%$10.19M$20K0.0010Gap Up Related Companies and Tools Related Companies BFRG Competitors CSCI Competitors CARM Competitors IMCC Competitors FLGC Competitors GOVX Competitors PHIO Competitors PHXM Competitors LGVN Competitors SONN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNSP) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access